Rothschild & Co Redburn initiated coverage of Bruker (BRKR) with a Buy rating and $60 price target representing 41% potential upside. Bruker has underperformed its life science equipment peers year-to-date, with revenue and margins pressured by academic and government budget cuts and tariffs, the analyst tells investors in a research note. However, the firm views the company as well positioned to return to above-market earnings growth from 2026, given its leadership in proteomics and demand for next-generation systems such as mass spectrometry.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR: